How AI is Accelerating the Scientific Method from Trial and Error to Targeted Discovery
Discovery science drives breakthroughs by uncovering patterns and correlations that guide new hypotheses. For example, researchers analyzing large genomic datasets without preset hypotheses can identify unexpected gene variants linked to diseases or reveal biological pathways worth exploring.
Traditionally, discovery science relied heavily on trial and error, involving unstructured exploration of vast data. This process is time-consuming and expensive, limiting how much discovery research can be performed and slowing innovation. It often takes years or even decades for initial ideas to lead to practical solutions.
AI is changing this dynamic. Nearly all life sciences organizations now use generative AI and agentic AI, with adoption rates higher than in other regulated industries. AI can shorten drug discovery timelines dramatically—from 5-6 years down to potentially just one year—and reduce R&D costs by 25-50 percent. This shift reduces the effort needed during discovery, speeding up the delivery of new drugs, therapies, and scientific insights.
Zeroing in on Areas Ripe for Experimentation
One major challenge in discovery science is deciding where to focus efforts. Large language models (LLMs) help researchers prioritize by quickly reviewing literature, highlighting critical focus areas, and formulating hypotheses faster than traditional methods allow.
AI also improves predictive modeling, enabling faster and more precise drug and compound design. Early modeling helps predict drug behavior in the body, allowing researchers to identify the most promising candidates before clinical trials. This reduces time, costs, and improves patient outcomes.
A global initiative uses AI to model human cells, a development seen as a key step forward in biology, potentially transforming how diseases are studied and treated.
Challenges and Considerations
AI supports a more iterative approach in life sciences by helping researchers learn from both successes and failures. It suggests experimental designs, optimizes procedures, and facilitates knowledge sharing across teams. This creates collaboration between humans and AI “coworkers.”
However, challenges remain. Life sciences companies often hesitate to share data, whereas academic institutions may be more open, causing friction in data access and governance. Integrating proprietary AI models that don’t communicate well can also hinder progress. Secure collaboration requires controlled access that protects data integrity and intellectual property.
To fully benefit from AI, organizations need unified platforms that support parallel experimentation and make insights accessible while maintaining governance. Moving from trial and error to targeted discovery demands a strategy that fosters human-AI collaboration, ensures security, and relies on a strong technical foundation. This approach enables faster innovation and the delivery of life-saving solutions.
Your membership also unlocks:
